Latest From Jessica Merrill
Biogen will pay Denali $560m up front plus a $465m equity investment in exchange for co-development and co-commercialization rights to clinical-stage LRRK2 inhibitors for Parkinson's disease.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.
The US FDA approved the esketamine nasal spray for adults with major depressive disorder with suicidal ideation or behavior, following its initial approval in 2019 for treatment-resistant depression.
The pandemic phase will last through late 2021/early 2022, becoming a more seasonal opportunity for several years after, Pfizer management predicted during the company's second quarter call.
Biosimilar competitors to Avastin, Herceptin and Rituxan and headwinds from COVID-19 are expected to have a CHF4.7bn negative impact in 2020, higher than the CHF4bn previously projected.
The US government’s order of 100 million doses for $1.95bn means the implied price for Pfizer/BioNtech's vaccine is $19.50 per dose. That could set a benchmark for solid near-term revenue and profitability for companies in the space.